ASND · Ascendis Pharma A/S · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-09-08 | Bodenhoff Mads |
SVP & PAO |
Convert↑
|
Ordinary Shares
|
3,000 |
| 2026-09-08 | Bodenhoff Mads |
SVP & PAO |
Sell↓
|
Ordinary Shares
|
3,000 |
| 2026-09-08 | Bodenhoff Mads |
SVP & PAO |
Convert↓
Filing footnotes — Warrants (Direct)
The warrants vested 25% on October 11, 2023 and thereafter in 36 equal monthly installments. |
Warrants
|
3,000 |
| 2026-09-02 | HOLTUG LARS |
Director |
Sell↓
|
Ordinary Shares
|
236 |
| 2026-08-14 | BIENAIME JEAN JACQUES |
Director |
Buy↑
Filing footnotes — Ordinary Shares (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $245.41 to $246.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
1,100 |
| 2026-08-14 | BIENAIME JEAN JACQUES |
Director |
Buy↑
Filing footnotes — Ordinary Shares (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $246.48 to $247.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
900 |
| 2026-06-02 | SMITH SCOTT THOMAS |
EVP & Chief Financial Officer |
Buy↑
|
Ordinary Shares
|
100 |
| 2026-05-29 | BIENAIME JEAN JACQUES |
Director |
Buy↑
|
Ordinary Shares
|
200 |
| 2026-05-29 | BIENAIME JEAN JACQUES |
Director |
Buy↑
|
Ordinary Shares
|
200 |
| 2026-05-29 | BIENAIME JEAN JACQUES |
Director |
Buy↑
|
Ordinary Shares
|
100 |
| 2026-05-29 | SMITH SCOTT THOMAS |
EVP & Chief Financial Officer |
Buy↑
|
Ordinary Shares
|
250 |
| 2026-05-26 | BIENAIME JEAN JACQUES |
Director |
Buy↑
Filing footnotes — Ordinary Shares (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $239.245 to $239.490 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
200 |
| 2026-05-26 | BIENAIME JEAN JACQUES |
Director |
Buy↑
Filing footnotes — Ordinary Shares (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $235.93 to $236.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
200 |
| 2026-05-11 | JENSEN FLEMMING STEEN |
See Remarks |
Sell↓
|
Ordinary Shares
|
19,460 |
| 2026-04-14 | BIENAIME JEAN JACQUES |
Director |
Other↓
Filing footnotes — Warrants (Direct)
The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments. |
Warrants
|
9,160 |
| 2026-04-14 | BIENAIME JEAN JACQUES |
Director |
Award↑
Filing footnotes — Warrants (Direct)
The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments. |
Warrants
|
9,160 |